Italia markets closed
  • FTSE MIB

    26.565,41
    -317,06 (-1,18%)
     
  • Dow Jones

    34.725,47
    +564,69 (+1,65%)
     
  • Nasdaq

    13.770,57
    +417,79 (+3,13%)
     
  • Nikkei 225

    26.717,34
    +547,04 (+2,09%)
     
  • Petrolio

    87,29
    +0,68 (+0,79%)
     
  • BTC-EUR

    33.835,00
    +535,37 (+1,61%)
     
  • CMC Crypto 200

    863,83
    +21,37 (+2,54%)
     
  • Oro

    1.792,30
    -2,70 (-0,15%)
     
  • EUR/USD

    1,1152
    +0,0005 (+0,04%)
     
  • S&P 500

    4.431,85
    +105,34 (+2,43%)
     
  • HANG SENG

    23.550,08
    -256,92 (-1,08%)
     
  • Euro Stoxx 50

    4.136,91
    -48,06 (-1,15%)
     
  • EUR/GBP

    0,8320
    -0,0008 (-0,10%)
     
  • EUR/CHF

    1,0375
    +0,0001 (+0,01%)
     
  • EUR/CAD

    1,4232
    +0,0044 (+0,31%)
     

Global Autism Clinical Trials Market Research Report, H2 2021 Review - ResearchAndMarkets.com

·3 minuto per la lettura

DUBLIN, December 08, 2021--(BUSINESS WIRE)--The "Autism - Global Clinical Trials Review, H2, 2021" clinical trials has been added to ResearchAndMarkets.com's offering.

The report provides an overview of Autism Clinical trials scenario. This report provides top line data relating to the clinical trials on Autism.

Report includes an overview of trial numbers and their average enrollment in top countries conducted across the globe. The report offers coverage of disease clinical trials by region, country (G7 & E7), phase, trial status, end points status and sponsor type. Report also provides prominent drugs for in-progress trials (based on number of ongoing trials).

. Clinical trials database undergoes periodic update by dynamic process. The report enhances the decision making capabilities and helps to create an effective counter strategies to gain competitive advantage.

Scope

  • The report provides a snapshot of the global clinical trials landscape

  • Report provides top level data related to the clinical trials by Region, Country (G7 & E7), Trial Status, Trial Phase, Sponsor Type and End point status

  • The report reviews top companies involved and enlists all trials (Trial title, Phase, and Status) pertaining to the company

  • The report provides all the unaccomplished trials (Terminated, Suspended and Withdrawn) with reason for unaccomplishment

  • The Report provides enrollment trends for the past five years

  • Report provides latest news for the past three months

Key Topics Covered:

  • Report Guidance

  • The Publisher Clinical Trials Report Coverage

  • Clinical Trials by Region

  • Clinical Trials and Average Enrollment by Country

  • Top Five Countries Contributing to Clinical Trials in Asia-Pacific

  • Top Five Countries Contributing to Clinical Trials in Europe

  • Top Countries Contributing to Clinical Trials in North America

  • Top Five Countries Contributing to Clinical Trials in Middle East and Africa

  • Top Five Countries Contributing to Clinical Trials in Central and South America

  • Clinical Trials by G7 Countries: Proportion of Autism to Central Nervous System Clinical Trials

  • Clinical Trials by Phase in G7 Countries

  • Clinical Trials in G7 Countries by Trial Status

  • Clinical Trials by E7 Countries: Proportion of Autism to Central Nervous System Clinical Trials

  • Clinical Trials by Phase in E7 Countries

  • Clinical Trials in E7 Countries by Trial Status

  • Clinical Trials by Phase

  • In Progress Trials by Phase

  • Clinical Trials by Trial Status

  • Clinical Trials by End Point Status

  • Subjects Recruited Over a Period of Time

  • Clinical Trials by Sponsor Type

  • Prominent Sponsors

  • Top Companies Participating in Autism Therapeutics Clinical Trials

  • Prominent Drugs

  • Clinical Trial Profile Snapshots

  • Appendix

Companies Mentioned

  • Otsuka Holdings Co Ltd

  • F. Hoffmann-La Roche Ltd

  • Teva Pharmaceutical Industries Ltd

  • Autism Speaks Inc

  • Johnson & Johnson

  • Seaside Therapeutics LLC

  • Bristol-Myers Squibb Co

  • Curemark LLC

  • Eli Lilly and Co

  • Finch Therapeutics Group Inc

For more information about this clinical trials report visit https://www.researchandmarkets.com/r/anmfck

View source version on businesswire.com: https://www.businesswire.com/news/home/20211208005776/en/

Contacts

ResearchAndMarkets.com
Laura Wood, Senior Press Manager
press@researchandmarkets.com
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900

Il nostro obiettivo è creare un luogo sicuro e coinvolgente in cui gli utenti possano entrare in contatto per condividere interessi e passioni. Per migliorare l’esperienza della nostra community, sospendiamo temporaneamente i commenti sugli articoli